Recombinant Human Angiotensin-Converting Enzyme 2 Uses, Dosage, Side Effects and more
Recombinant Human Angiotensin-Converting Enzyme 2 is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
| Attribute | Details |
|---|---|
| Trade Name | Recombinant Human Angiotensin-Converting Enzyme 2 |
| Generic | Alunacedase alfa |
| Alunacedase alfa Other Names | Alunacedase alfa, Recombinant Human Angiotensin-Converting Enzyme 2, rhACE2 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Recombinant Human Angiotensin-Converting Enzyme 2 works
Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.
